Tarsus Pharmaceuticals (TARS) Stock Price

$47.84 1.8%

Sign up
to add to portfolio

AI Score

Hold
  • Alternative

    7
  • Fundamental

    7
  • Technical

    6

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Tarsus Pharmaceuticals, AI stock picks, stock alerts and much more.

Sign up

TARS AI Stock Analysis

Financial Performance

Tarsus Pharmaceuticals has shown strong financial performance with its revenue growing by 268% year over year to $48.1M in the last quarter. Similarly, gross profit surged by 278.4% YoY to reach $44.9M, indicating a healthy margin level for the company. However, it's important to note that operating income is still negative at -$25.2M but has improved by 43.4% YoY indicating that the company is working towards profitability.

Stock Price

The stock price of Tarsus Pharmaceuticals is currently trading at $52.69 and has seen an impressive growth of 138.4% YoY and a slight increase of 0.4% in the last month alone which shows investor confidence in the company's prospects despite its negative PE ratio of -14.05 and EPS of -3.75 suggesting high future earnings growth expectations from investors.

Alternative Data Signals

In terms of alternative data signals, web traffic has decreased significantly by -61.% MoM which could be a potential red flag as it might indicate declining interest or engagement with the company's products or services online but this needs further investigation before drawing any conclusions.

On a positive note, job postings have increased significantly by 50% MoM and up by 84.6% YoY signifying business expansion plans while social media followership on Twitter, Instagram and Facebook have also been increasing steadily over time which indicates improving brand awareness among consumers.

Conclusion

In conclusion, based on Tarsus Pharmaceuticals' solid revenue growth, steady stock price appreciation despite current lack of profitability and mixed alternative data signals (increasing job postings & social media followers but decreasing web traffic), the outlook for Tarsus Pharmaceuticals' stock is cautiously bullish.

Note: This AI Stock Analysis is based on data as of January 11. Our members can refresh and get access to an up-to-date AI stock analysis.

Sign up

Tarsus Pharmaceuticals (TARS) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Tarsus Pharmaceuticals (TARS), currently trading at $47.84, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About TARS

LSE
  • Tarsus Pharmaceuticals, Inc.

  • Symbol

    TARS

  • Market

    NASDAQ

  • Industry

    Biotechnology

  • Market Cap

    1.8B

Similar Stocks

CPRX Catalyst Pharmaceuticals
CPRX
$21.62
2%
6
INO Inovio Pharmaceuticals
INO
$2.24
0.9%
2
MRNA Moderna
MRNA
$35.53
5.3%
4
AVXL Anavex Life Sciences
AVXL
$8.35
3.8%
6
BBIO BridgeBio Pharma
BBIO
$36.85
0.1%
6

TARS Alternative Data

Web Traffic

Tarsus Pharmaceuticals receives an estimated 40309 monthly visitors to tarsusrx.com.

  • Web Traffic

    40309

  • Change from Previous Month

    85.9%

  • 3 Month Change

    29.2%

Reddit Mentions

Tarsus Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

News Mentions

Tarsus Pharmaceuticals was mentioned 0 times in the news yesterday.

  • News Mentions

    0

  • Daily Change

    100%

  • 1 Month Change

    100%

  • 3 Month Change

    100%

Twitter Followers

Tarsus Pharmaceuticals has 609 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.7% over the last month.

  • Twitter Followers

    609

  • Daily Change

    0.2%

  • 1 Month Change

    0.7%

  • 3 Month Change

    1.8%

Facebook Engagement

Tarsus Pharmaceuticals has engaged 0 users via their Facebook Page over the last 7 days.

  • Facebook Engagement

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    100%

Instagram Followers

Tarsus Pharmaceuticals has 1,103 Instagram Followers on its main Instagram account, up by 0.7% over the last month.

  • Instagram Followers

    1103

  • Daily Change

    0.2%

  • 1 Month Change

    0.7%

  • 3 Month Change

    3.3%

LinkedIn Followers

24,741 are following Tarsus Pharmaceuticals on LinkedIn, up by 3.3% over the last month.

  • LinkedIn Followers

    24741

  • Daily Change

    0.1%

  • 1 Month Change

    3.3%

  • 3 Month Change

    10.5%

Job Postings

Tarsus Pharmaceuticals has an estimated 17 open job postings, which is down -32% over the last month.

  • Job Postings

    17

  • Daily Change

    0%

  • 1 Month Change

    32%

  • 3 Month Change

    54.5%

LinkedIn Employees

According to LinkedIn, Tarsus Pharmaceuticals has 337 employees, up by 2.4% over the last month.

  • LinkedIn Employees

    337

  • Daily Change

    0%

  • 1 Month Change

    2.4%

  • 3 Month Change

    3.4%

Business Outlook
  • Business Outlook

    100

  • Change from Previous Month

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

TARS Financials

TARS Key Metrics
  • Total Revenue

    $48.1M

  • Net Income

    -$23.4M

  • Earnings per Share

    -$0.61

  • Free cash flow

    -$8.9M

  • EBITDA

    -$20.7M

  • EBITDA Ratio

    -0.429673

  • Total Assets

    $376.3M

TARS 2-year Revenue & Income
TARS 2-year Free Cash Flow

TARS Technicals

TARS SMA
TARS RSI

FAQ

What's the current price of Tarsus Pharmaceuticals (TARS) Stock?
The price of an Tarsus Pharmaceuticals (TARS) share is $47.84.

What's the market cap of Tarsus Pharmaceuticals?
The current market cap of Tarsus Pharmaceuticals is 1.8B.

Should I buy or sell TARS?
Multiple alternative data signals suggest that Tarsus Pharmaceuticals stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.

Is Tarsus Pharmaceuticals a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in Tarsus Pharmaceuticals stock. The bullish indicators suggest that Tarsus Pharmaceuticals' growth prospects and market position may lead to a positive performance in the foreseeable future.

Is now a good time to buy Tarsus Pharmaceuticals (TARS) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying Tarsus Pharmaceuticals stock, given the bullish outlook.

What are some stocks similar to Tarsus Pharmaceuticals (TARS) that investors often compare it to?
Tarsus Pharmaceuticals (TARS) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.

What is the forecast for Tarsus Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Tarsus Pharmaceuticals' stock price to be around $51.38 in 2026. Starting from the current price of $47.84, this represents a 7.4% change in price, indicating a bullish outlook for the stock.

How to buy Tarsus Pharmaceuticals (TARS) Stock?
Tarsus Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Tarsus Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.